These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 1398742)

  • 41. Lysis of herpes simplex virus-infected cells by lymphokine-activated killer cells.
    Chu CT; Lee P; Lin BJ; Sun MJ; Hsieh KH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Feb; 24(1):108-18. PubMed ID: 1657543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
    Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
    Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
    Komatsu F; Kajiwara M
    Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells.
    Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y
    Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Capacity of tumor necrosis factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma.
    Bowman RV; Manning LS; Davis MR; Robinson BW
    Clin Immunol Immunopathol; 1991 Jan; 58(1):80-91. PubMed ID: 1983971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen.
    Baral E; Nagy E; Berczi I
    Int J Cancer; 1996 Apr; 66(2):214-8. PubMed ID: 8603814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
    Savas B; Cole SP; Tsuruo T; Pross HF
    J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells--a mechanism affecting the human lung microenvironment?
    Zambello R; Trentin L; Enthammer C; Cipriani A; Agostini C; Semenzato G
    Clin Exp Immunol; 1996 Aug; 105(2):383-8. PubMed ID: 8706349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of CD18 in lymphokine activated killer (LAK) cell-mediated lysis of human monocytes: comparison with other LAK targets.
    Blanchard DK; Hall RE; Djeu JY
    Int J Cancer; 1990 Feb; 45(2):312-9. PubMed ID: 1968054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
    Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
    J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of heat shock on cytolysis mediated by NK cells, LAK cells, activated monocytes and TNFs alpha and beta.
    Jäättelä M
    Scand J Immunol; 1990 Feb; 31(2):175-82. PubMed ID: 2309100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heterogeneity of the lymphokine-activated killer cell phenotype.
    Chadwick BS; Miller RG
    Cell Immunol; 1991 Jan; 132(1):168-76. PubMed ID: 1829653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokine modulation of the susceptibility of acute T-lymphoblastic leukemia cell lines to LAK activity.
    Cesano A; Clark SC; Santoli D
    Leukemia; 1993 Mar; 7(3):404-9. PubMed ID: 8445946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of lymphokine-activated killer cells of equine origin: specificity for equine target cells.
    Hormanski CE; Truax R; Pourciau SS; Folsom RW; Horohov DW
    Vet Immunol Immunopathol; 1992 Apr; 32(1-2):25-36. PubMed ID: 1604800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of malignant cell clonogenic capacities and position along the maturation pathway on their susceptibility to lymphokine-activated killer cell cytotoxicity.
    Thomas X; Anglaret B; Adeleine P; Maritaz O; Bailly M; Fiere D; Archimbaud E
    Leuk Lymphoma; 1998 Jan; 28(3-4):343-53. PubMed ID: 9517505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of IFN-gamma treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokine-activated killer (LAK) cell lysis in vitro; association with H-2 expression on the target cells.
    Tsai L; Ohlén C; Ljunggren HG; Kärre K; Hansson M; Kiessling R
    Int J Cancer; 1989 Oct; 44(4):669-74. PubMed ID: 2507452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.
    Fady C; Gardner A; Gera JF; Lichtenstein A
    Cancer Immunol Immunother; 1993 Oct; 37(5):329-36. PubMed ID: 8104695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MHC class I up-regulation protects some but not all targets against LAK-mediated lysis: possible implications for the existence of LAK cell subpopulations using different recognition strategies.
    Sarin A; Haridas V; Saxena RK
    Immunol Lett; 1993 Sep; 38(1):59-62. PubMed ID: 8300155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.